Zhanlgas Daniyarov

Zhalgas Daniyarov is Public Affairs & Government Relations Manager at AstraZeneca Kazakhstan and a member of AmCham’s Healthcare Committee.  

He brings extensive experience in public sector engagement and strategic communications across the pharmaceutical industry and beyond, having held roles at Sanofi, Merck, Shell, and NCOC.  

Zhalgas focuses on building constructive, transparent dialogue between industry stakeholders and government authorities to advance patient-centered health policies, strengthen regulatory frameworks, and support innovation-driven growth. 

Trained as a policy lawyer, Zhalgas graduated from the Kazakhstan Institute of Law and International Relations (Jurisprudence) and later earned a degree in Public Administration from Istanbul University.  

This dual background in law and public administration enables him to navigate complex policy environments, align compliance with practical implementation, and translate regulatory priorities into actionable programs. 

Within the Healthcare Committee, Zhalgas contributes expertise on three core areas: protecting patients’ rights and interests, safeguarding intellectual property, and shaping regulatory and legislative developments in the pharmaceutical sector.  

He has worked on initiatives that improve access to medicines, enhance health system resilience, and promote ethical, evidence-based decision-making.  

His approach emphasizes data-informed advocacy, cross-sector partnerships, and patient engagement as pillars of sustainable healthcare reform. 

Zhalgas is fluent in Russian, Kazakh, Turkish and English, facilitating multi-stakeholder collaboration and international best-practice exchange.  

He is committed to fostering an environment where innovation, quality, and affordability converge – ensuring that regulatory modernization and IP protection ultimately serve patients and public health priorities.  

As part of the AmCham Healthcare Committee, he aims to support pragmatic solutions that align global standards with local needs, strengthen the investment climate, and accelerate the delivery of high-impact therapies to patients across Kazakhstan.